You are here

AlloVir

AlloVir's cell therapy tackles infection in midphase kidney transplant trial

Fierce Biotech

Wed, 02/15/23 - 10:46 am

kidney transpants

clinical trials

Gilead again backs AlloVir's T cell therapy in $127M direct offering

Endpoints

Wed, 07/27/22 - 10:53 am

Gilead Sciences

Two Cell Therapy Companies Bag New CEOs

BioSpace

Tue, 03/23/21 - 10:35 am

Abeona Therapeutics

Another huge quarter for biotech flotations

EP Vantage

Fri, 10/2/20 - 12:52 pm

Relay Therapeutics

Dyne Therapeutics

Annexon Biosciences

AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients

Xconomy

Thu, 07/30/20 - 11:20 pm

organ transplant

This week's wave of biotech IPO players bumps up offerings and targets bigger harvests of cash

Endpoints

Thu, 07/23/20 - 11:16 am

Nurix Therapeutics

AlloVir, Baylor ally to develop COVID-19 T-cell therapy

Fierce Biotech

Mon, 03/23/20 - 11:42 am

t-cell therapies

David Hallal brings his first cell therapy company into the fold, and it's tied to a major league financing deal

Endpoints

Wed, 05/22/19 - 09:53 am